[
  {
    "ts": "2025-03-21T15:56:19+00:00",
    "headline": "Why Incyte Stock Was Tanking This Week",
    "summary": "A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days.  On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa.  In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.",
    "url": "https://www.fool.com/investing/2025/03/21/why-incyte-stock-was-tanking-this-week/?source=eptyholnk0000202&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=cb107194-a50f-4c0f-a86b-2379ee680130",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9c79c869-49df-38e0-9bc7-e93883f8ca7d",
      "content": {
        "id": "9c79c869-49df-38e0-9bc7-e93883f8ca7d",
        "contentType": "STORY",
        "title": "Why Incyte Stock Was Tanking This Week",
        "description": "",
        "summary": "A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days.  On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa.  In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.",
        "pubDate": "2025-03-21T15:56:19Z",
        "displayTime": "2025-03-21T15:56:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b9a0450c6ce50ea778463bc0712ae166",
          "originalWidth": 6720,
          "originalHeight": 4480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TBoYZKMiMIpkJR26szESTg--~B/aD00NDgwO3c9NjcyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/b9a0450c6ce50ea778463bc0712ae166.cf.webp",
              "width": 6720,
              "height": 4480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6A2X4jYMf5szg5gYq7fyXg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b9a0450c6ce50ea778463bc0712ae166.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/03/21/why-incyte-stock-was-tanking-this-week/?source=eptyholnk0000202&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=cb107194-a50f-4c0f-a86b-2379ee680130",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-incyte-stock-tanking-week-155619459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-21T13:01:08+00:00",
    "headline": "1 Healthcare Stock on Our Watchlist and 2 to Brush Off",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.",
    "url": "https://finance.yahoo.com/news/1-healthcare-stock-watchlist-2-130108923.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "b2336a56-8913-3c7f-a038-9957a6b34b6a",
      "content": {
        "id": "b2336a56-8913-3c7f-a038-9957a6b34b6a",
        "contentType": "STORY",
        "title": "1 Healthcare Stock on Our Watchlist and 2 to Brush Off",
        "description": "",
        "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.",
        "pubDate": "2025-03-21T13:01:08Z",
        "displayTime": "2025-03-21T13:01:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "INCY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9ebFa.LFGXWDaOAygGvuNg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ojCguUNIH7INClq6_Rac1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-watchlist-2-130108923.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-watchlist-2-130108923.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "UFPT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-21T08:46:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
    "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sarepta-084600176.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8134e7ee-fd64-38d8-882c-ff9d58bb8500",
      "content": {
        "id": "8134e7ee-fd64-38d8-882c-ff9d58bb8500",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
        "description": "",
        "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
        "pubDate": "2025-03-21T08:46:00Z",
        "displayTime": "2025-03-21T08:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sarepta-084600176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sarepta-084600176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SRPT"
            },
            {
              "symbol": "VTVT"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]